Galera Therapeutics, Inc. — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/618a1f56-e7c6-40f5-8a25-0d104b135559/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-2.5M | 2025-01-01 – 2025-12-31 | evidence 0001563577-26-000005 |
| FY 2024 | $-20.2M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-047798 |
| FY 2023 | $-49.3M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-037614 |
| FY 2022 | $-51.2M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-006588 |
| FY 2021 | $-73.4M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-003292 |
| FY 2020 | $-70.6M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-012244 |
| FY 2019 | $-50.7M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-009542 |
| FY 2018 | $-24.3M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-009542 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).